Authors
- Xin Shi * 1
- Hongli Gao 2
- Qian Zhao 3
- Mengqi Zhuang 2
Abstract
This research aimed to investigate the safety and efficacy of inhibitors of programmed cell death 1 and its ligand in the postoperative chemotherapy for advanced colorectal cancer. Patients with advanced colorectal cancer treated in our hospital from June 2019 to June 2021 were included (23 patients receiving Apatinib served as the control group and 28 patients receiving programmed cell death protein 1 inhibitor served as the experiment group). The safety and clinical efficacy of these two treatments were analyzed. The experiment group showed 7.1% of objective remission rate and 89.3% of disease control rate while the Apatinib group showed 8.7% of objective remission rate and 56.5% of disease control rate. The experiment group also showed higher progression-free survival (6.4 months) than Apatinib group (3.9 months) (P = 0.0209). Patients with no V-Ki-ras2 Kirsten ratsarcoma viral oncogene homolog wild-type, liver metastases and left-sided colon tumors could benefit from the experiment group. No significant difference was observed in adverse events between the 2 groups, and 8 patients (15.7%) in total had treatment-related grade 3 adverse event. To sum up, inhibitor of programmed cell death protein 1 and its ligand is efficacious for advanced colorectal cancer, with well safety and tolerance.
